Drug Safety in the Post-Vioxx Era

New legislation, regulation and company strategies in Europe and the US

Implement a variety of proactive management, marketing, distribution and technological strategies to ensure the safety of your products and prevent exposure of drug safety issues for the public.

'Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US', is a new report which examines the actions taken by legislative and regulatory bodies in response to recent drug safety concerns surrounding the COX-2 inhibitors and antidepressants.

Develop a tighter drug safety strategy by analyzing nine case studies describing safety issues encountered by pharmaceutical companies and examine the predictions for the future of drug safety regulation in the US and EU.

Top 3 reasons to order this report today...

• Benchmark your drug safety strategy against your competitors by analyzing management, marketing and technological strategies companies are pursuing.
   
• Anticipate regulatory and legislative changes in Europe and the US that may impact how you address drug safety issues and assess potential changes that may need to be made to your current drug safety strategy.
   
• Develop innovative future strategies by utilizing the report's nine case studies of leading pharmaceutical companies including GlaxoSmithKline, Pfizer, AstraZeneca, Eli Lilly and Merck & Co.

Price - $1900
Publication Date – July 2005

To order click the title: Drug Safety in the Post-Vioxx Era - New legislation, regulation and company strategies in Europe and the US

To order these reports contact peter.barfoot@bioportfolio.com or telephone +44 1300 321501 or +1 415 680 2472 and a representative will get back to you.

You can also order on line at: http://www.bioportfolio.com/cgi-bin/acatalog/search.html